Evidence map›Paper›PMID 31808831›Full record

ReviewHematology. American Society of Hematology. Education Program2019

New advances in the diagnosis of von Willebrand disease.

Ruchika Sharma, Sandra L Haberichter

Registry-linked trialOpen access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology. American Society of Hematology. Education Program, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07410130 (Clinical Spectrum of Von Willebrand Disease Among Children), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07410130 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Clinical Spectrum of Von Willebrand Disease Among Children: Frequency, Management, and Outcomes in Assiut Governorate

TypeobservationalSponsorAssiut UniversityRan2026 to 2026Enrolled25ConditionsVon Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic DisordersArmsTranexamic Acid, Von Willebrand Factor-Containing Concentrates
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. [Chinese guideline on the diagnosis and management of von Willebrand disease (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Guideline
  2. Article
  3. Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ruchika SharmaDiagnostic Laboratories and Blood Research Institute, Versiti, Milwaukee, WI.
Sandra L HaberichterDiagnostic Laboratories and Blood Research Institute, Versiti, Milwaukee, WI.
Medical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

von Willebrand disease (VWD) is the most common autosomal inherited bleeding disorder, with an estimated prevalence of 1 in 1000 individuals. VWD is classified into quantitative and qualitative forms. Diagnosis of VWD is complex and requires (1) a personal history of bleeding symptoms, (2) family history of bleeding or VWD, and (3) confirmatory laboratory testing. There are certain bleeding assessment tools to objectively measure bleeding symptoms in patients that have been shown to correlate with the diagnosis as well as the severity of VWD. Laboratory diagnosis requires at least initially a measurement of von Willebrand factor (VWF) antigen levels, VWF platelet binding activity (VWF:RCo, VWF:GPIbM, and VWF:GPIbR), and factor VIII (FVIII) activity. Additional testing to confirm the specific subtype may include VWF collagen binding activity, low-dose ristocetin VWF-platelet binding, FVIII-VWF binding, VWF multimer analysis, and VWF propeptide antigen. Recent advances have been made regarding some of these assays. Molecular testing in VWD is not found to be useful in "low VWF" or most type 1 VWD cases but may be informative in patients with severe type 1 VWD, type 1C VWD, type 2 VWD, or type 3 VWD for accurate diagnosis, genetic counseling, and appropriate treatment. The diagnostic algorithm for VWD is complex, but advances continue to be made in improving VWF functional assays and diagnostic pathways.

Indexed as

Factor VIIIvon Willebrand Diseasesvon Willebrand FactorBlood PlateletsChild, PreschoolFemaleGenetic CounselingHemorrhageHumansPlatelet Function TestsF8 protein, humanFactor VIIIvon Willebrand Factor

Identifiers

PMID31808831
PMCPMC6913428
OpenAlexW2994577528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.